Law360 (December 1, 2020, 9:47 PM EST) — A biosimilars and generic-drug industry trade group has urged federal lawmakers to set their sights on measures to ensure that patients can more easily get their hands on biosimilars, rein in allegedly anti-competitive conduct related to brand-name medicines and make updates to Medicare Part D.
In Monday letters to all members of the U.S. House of Representatives and U.S. Senate, the Association for Accessible Medicines President and CEO Dan Leonard laid out what it wants Congress to focus on and support moving forward, emphasizing the importance of expanding the ability of patients to get access to biosimilars,
“Ensuring the generics…
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!